NetworkNewsBreaks – Brain Scientific Inc. (BRSF)
Post# of 129
(Total Views: 138)
Posted On: 08/27/2021 4:27:14 PM
NetworkNewsBreaks – Brain Scientific Inc. (BRSF) Modernizing, Increasing Accessibility to Brain Diagnostics
Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is fulfilling its mission of modernizing and increasing accessibility to brain diagnostics with its FDA-cleared NeuroCap(TM) and NeuroEEG(TM), which are already patented in the United States, China and Europe. As the company’s first commercialized devices, they are designed to disrupt the current electroencephalogram (“EEG”) market by offering a cost-effective and disposable alternative to existing solutions. A recent article reads, “Brain Scientific’s development process spans three stages. The first development phase, from 2018 to 2019, resulted in the inception of the company’s portable, clinical-grade, easy-to-use neurological devices. The second, ongoing phase currently focuses on the creation of cloud-based, secure infrastructure to transmit patient data between patients and neurologists. The final and third phase — scheduled for 2021 to 2023 — aims to focus on the use of AI to facilitate diagnostic analysis and increase the consistency, efficiency and accuracy of imaging by neurology specialists. Brain Scientific plans on expanding the vision for telemedicine in neurology with an aim to address the current acute neurologist shortfall throughout the U.S.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is fulfilling its mission of modernizing and increasing accessibility to brain diagnostics with its FDA-cleared NeuroCap(TM) and NeuroEEG(TM), which are already patented in the United States, China and Europe. As the company’s first commercialized devices, they are designed to disrupt the current electroencephalogram (“EEG”) market by offering a cost-effective and disposable alternative to existing solutions. A recent article reads, “Brain Scientific’s development process spans three stages. The first development phase, from 2018 to 2019, resulted in the inception of the company’s portable, clinical-grade, easy-to-use neurological devices. The second, ongoing phase currently focuses on the creation of cloud-based, secure infrastructure to transmit patient data between patients and neurologists. The final and third phase — scheduled for 2021 to 2023 — aims to focus on the use of AI to facilitate diagnostic analysis and increase the consistency, efficiency and accuracy of imaging by neurology specialists. Brain Scientific plans on expanding the vision for telemedicine in neurology with an aim to address the current acute neurologist shortfall throughout the U.S.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Brain Scientific, Inc. (BRSF) Stock Research Links
Scroll down for more posts ▼